{[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-({[({[(3R)-3-{[2-({2-[({[2-(5-bromoindol-3-yl)ethyl]carbamoyl}methyl)sulfanyl]ethyl}carbamoyl)ethyl]carbamoyl}-3-hydroxy-2,2-dimethylpropoxy](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]oxy}methyl)-4-hydroxyoxolan-3-yl]oxy}phosphonic acid

• ChemBase编号: 3029
• 分子式: C33H47BrN9O17P3S
• 平均质量: 1046.666663
• 单一同位素质量: 1045.12068398
• SMILES: CC(C)(CO[P@@](=O)(O)O[P@](=O)(O)OC[C@@H]1O[C@H]([C@H](O)[C@H]1OP(=O)(O)O)n1cnc2c1ncnc2N)[C@@H](O)C(=O)NCCC(=O)NCCSCC(=O)NCCc1c[nH]c2ccc(Br)cc12
• Canonical SMILES: O=C(NCCSCC(=O)NCCc1c[nH]c2c1cc(Br)cc2)CCNC(=O)[C@@H](C(CO[P@](=O)(O[P@@](=O)(OC[C@@H]1O[C@H]([C@@H]([C@H]1OP(=O)(O)O)O)n1cnc2c1ncnc2N)O)O)(C)C)O
• InChI: InChI=1S/C33H47BrN9O17P3S/c1-33(2,28(47)31(48)38-8-6-23(44)37-9-10-64-14-24(45)36-7-5-18-12-39-21-4-3-19(34)11-20(18)21)15-57-63(54,55)60-62(52,53)56-13-22-27(59-61(49,50)51)26(46)32(58-22)43-17-42-25-29(35)40-16-41-30(25)43/h3-4,11-12,16-17,22,26-28,32,39,46-47H,5-10,13-15H2,1-2H3,(H,36,45)(H,37,44)(H,38,48)(H,52,53)(H,54,55)(H2,35,40,41)(H2,49,50,51)/t22-,26+,27-,28-,32+/m0/s1
• InChIKey: BBDVCGJBELWXIQ-KOGRCXSVSA-N

名称和登记号

名称

• IUPAC标准名: {[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-({[({[(3R)-3-{[2-({2-[({[2-(5-bromoindol-3-yl)ethyl]carbamoyl}methyl)sulfanyl]ethyl}carbamoyl)ethyl]carbamoyl}-3-hydroxy-2,2-dimethylpropoxy](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]oxy}methyl)-4-hydroxyoxolan-3-yl]oxy}phosphonic acid
• IUPAC传统名: @coa-S-acetyl 5-bromotryptamine
• 别名: Coa-S-Acetyl 5-Bromotryptamine

登记号

• PubChem SID: 46505411; 160966476
• PubChem CID: 46936647

理论计算性质

JChem

• Acid pKa: 0.8136577
• 质子受体: 18
• 质子供体: 10
• LogD (pH = 5.5): -8.796466
• LogD (pH = 7.4): -10.403712
• Log P: -6.8878713
• 摩尔折射率: 226.911 cm^3
• 极化性: 90.61587 Å^3
• 极化表面积: 388.55 Å^2
• 可自由旋转的化学键: 24
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: 0.49
• LOG S: -2.71
• 溶解度: 2.04e+00 g/l

详细说明

DrugBank - DB03341

Drug information: experimental